

Liberia

Support for Vaccine: Yellow Fever

This Decision Letter sets out the Programme Terms of a Programme

1. **Country:** Liberia

2. **Vaccine grant number:** LBR-YF-R,LBR-YF-R-VAC,LBR-YF-R-VIG,LBR-YF-R-VIG-MOH

3. **Date of Decision Letter:** 20 July 2020

4. **Date of the Partnership Framework Agreement:** 19 August 2013

5. **Programme title:** New Vaccine Support (NVS), Yellow Fever, Routine

6. **Vaccine type:** Yellow Fever

7. **Requested product presentation and formulation of vaccine:**

Requested product presentation and formulation of vaccine: YF, YF, 10 doses/vial, lyophilised

8. **Programme duration:**¹ 2001-2020

9. **Programme Budget (indicative):**² (subject to the terms of the Partnership Framework Agreement, if applicable)

	2001-2019	2020	2021	2022	2023	2024	Total ²
Programme Budget(US\$)	2,562,665	246,856	-	-	-	-	2,809,521

10. **Vaccine introduction grant:**

Approval		
Year	Grant number	Amount (US\$)
2002	LBR-YF-R-VIG-MOH	100,000

11. **Product switch grant:**

Not applicable

¹This is the entire duration of the programme.

²This is the total amount endorsed by Gavi for the entire duration of the programme.

³This is the amount that Gavi has approved.



12. Indicative annual amounts:³ (subject to the terms of the Partnership Framework Agreement, if applicable)

Type of supplies to be purchased with Gavi funds	2001-2019	2020	2021
Number of vaccine doses	-	181,800	-
Number of AD syringes	-	73,048	-
Number of re-constitution syringes	-	8,036	-
Number of safety boxes	-	900	-
Annual Amounts (US\$)	2,562,665	227,923	-

13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

14. Self-procurement:
Not applicable

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group:	Initial self-financing				
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.					
Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024
Number of vaccine doses	35,200	-	-	-	-
Number of AD syringes	-	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	-	-	-	-	-
Value of vaccine doses (US\$)	41,536	-	-	-	-
Total co-financing payments (US\$) (including freight)	43,407	-	-	-	-

16. Operational support for campaigns:

Not applicable

17. Additional Reporting Requirements:

Reports and other information :	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> • vaccine stock levels including buffer stock, by end of March; • number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. • Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 15 May</p>
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Gavi Secretariat</p>

18. Financial clarifications: Country shall provide the following clarifications to Gavi* :

* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.

19. Other conditions:

Signed by:

On behalf of Gavi



Pascal Bijleveld

Director, Country Support

13 July 2020